stockrow
Monday 9 November 2026
Export AYTU’s income statement to Excel — free account
Aytu BioPharma, Inc.
AYTUHealthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.
- Revenue
- +6.42%
- EPS
- +100.0%
- Free cash flow
- +57.7%
- Total debt
- −21.9%
Quarter to June 2026, against a year earlier
1.83
0.02
+1.10%
Follow AYTU
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.28 | 0.42 | 0.51 | 0.46 | |
P/FCF ratio |
0.00 | 0.00 | 18.22 | 8.19 | |
P/Operating CF |
(28.72) | 7.10 | (6.86) | 6.01 | |
P/B ratio |
0.77 | 1.84 | 0.82 | 0.75 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.19 | 0.27 | 0.42 | 0.30 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.01) | (28.57) | 14.18 | 5.25 | |
EV/FCF |
(13.29) | (30.74) | 15.11 | 5.32 | |
Quick Ratio |
1.00 | 0.93 | 0.85 | 0.90 | |
Current Ratio |
1.23 | 1.16 | 1.12 | 1.13 | |
Net Debt/EBITDA |
8.11 | 8.61 | 1.68 | (24.94) | |
Debt/Assets |
21.74% | 17.16% | 19.53% | 16.22% | |
Debt/Equity |
1.17 | 1.47 | 0.62 | 0.48 | |
Asset Turnover |
0.53 | 0.53 | 0.48 | 0.50 | |
Operating CF/Net income |
(0.31) | (0.35) | 0.74 | (293.73) | |
Capex/Depreciation |
0.00 | (0.02) | 0.00 | (0.01) | |
Interest Coverage |
(2.91) | (3.52) | (9.32) | (2.03) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
73.78% | 72.98% | 87.84% | 64.73% | |
Intangible Assets out of Total Assets |
0.33 | 0.36 | 0.38 | 0.39 | |
Share Based Compensation of Revenue |
0.82% | 1.87% | 1.19% | 0.91% | |
Graham Net Nets |
(1.17) | (1.21) | (0.32) | (0.30) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(102.66%) | (119.62%) | (157.14%) | (63.72%) | |
Free Cash Flow Yield |
(5.21%) | (2.12%) | 5.49% | 12.21% | |
Revenue per Share |
1.47 | 1.51 | 1.18 | 1.31 | |
Operating CF per Share |
(0.07) | 0.37 | (0.40) | 0.36 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | 0.36 | (0.40) | 0.36 | |
Cash per Share |
3.46 | 2.99 | 2.54 | 2.14 | |
Shareholders Equity per Share |
2.45 | 1.42 | 3.34 | 2.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.45 | 1.42 | 3.34 | 2.86 | |
Free Cash Flow |
(0.62) | 3.66 | (4.18) | 4.39 | |
Working Capital |
15.12 | 10.68 | 7.35 | 7.10 | |
Capital Expenditures |
— | (0.02) | 0.00 | (0.01) | |
Net Current Asset Value |
(20.71) | (31.56) | (9.22) | (7.97) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
28.19 | 28.16 | 30.16 | 26.97 | |
Average Payables |
12.93 | 12.98 | 12.63 | 10.94 | |
Average Inventory |
10.92 | 9.87 | 9.26 | 9.15 | |
Average Assets |
120.41 | 119.11 | 117.95 | 114.59 | |
Average Common Equity |
26.50 | 22.48 | 35.02 | 27.12 |
Columns are period end dates · fundamentals updated 2 Nov 2026